The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Expected to Reach $4,083.2 Million by 2033

Dublin, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy Market by Diagnosis, by Treatment by End-User, and by Region - Global Forecast to 2023-2033" report has been added to * ResearchAndMarkets.com's* offering.

The global chronic inflammatory demyelinating polyneuropathy (CIDP) market size was $1,852.4 million in 2022 and is expected to reach at $4,083.2 million by 2033 with a CAGR of 7.45% during the forecast period 2023 to 2033.

The growing prevalence of CIDP, increasing research and development activity, advancements in medical technology, and expanding healthcare infrastructure is projected to drive market growth in the near future. Furthermore, rising approval and product launches are some other factors supporting the market growth. However, lack of awareness is expected to hamper the market growth.

Medical technology advancements have resulted in the development of more effective and targeted treatments for CIDP. This is expected to increase the adoption of these treatments, propelling the CIDP market forward. For instance, the European Commission approved Uplizna (inebilizumab) in December 2021 for the treatment of adult patients with CIDP who are positive for paranodal antibodies. Uplizna is a monoclonal antibody that targets B cells and has been shown in clinical trials to reduce CIDP disease activity and disability.

The increasing research and development activities in the field of CIDP are expected to lead to the development of new and more effective treatments for the disease, driving the growth of the CIDP market. For instance, Grifols announced the launch of CUVITRU (immune globulin subcutaneous [human], 20% solution) in the United States in August 2021 for the treatment of CIDP. CUVITRU is a subcutaneous immunoglobulin therapy that has been shown in clinical trials to be effective in the treatment of CIDP.

*Companies Mentioned*

· Grifols
· CSL Behring
· Shire
· Octapharma
· Kedrion Biopharma
· Pfizer
· Baxter International

*Segmentation: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2022 - 2033*

*By Diagnosis (Revenue, USD Million), 2022 - 2033*

· Electromyography (EMG)
· Nerve Conduction Study (NCS)
· Lumbar Puncture
· Magnetic Resonance Imaging (MRI)
· Others

*By Treatment (Revenue, USD Million), 2022 - 2033*

· Intravenous Immunoglobulin (IVIG)
· Corticosteroids
· Plasmapheresis
· Physiotherapy
· Immunosuppressants

*By End User (Revenue, USD Million), 2022 - 2033*

· Hospitals
· Homecare
· Specialty Clinics
· Research Institutes

*By Region (Revenue, USD Million), 2022 - 2033*

*North America*

· U.S.
· Canada

*Europe*

· Germany
· France
· UK
· Spain
· Italy
· Rest of Europe

*Asia Pacific*

· China
· Japan
· India
· Australia
· South Korea
· Rest of APAC

*Latin America*

· Brazil
· Mexico
· Argentina
· Rest of LATAM

*Middle East & Africa*

· South Africa
· GCC
· Rest of MEA

*Key Attributes:*

*Report Attribute* *Details*
No. of Pages 200
Forecast Period 2022 - 2033
Estimated Market Value (USD) in 2022 $1852.4 Million
Forecasted Market Value (USD) by 2033 $4083.2 Million
Compound Annual Growth Rate 7.4%
Regions Covered Global

For more information about this report visit https://www.researchandmarkets.com/r/di29e8

*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900